The worldwide obesity epidemic represents a severe threat to global health and is driving the scientific quest for a greater understanding of the mechanisms that regulate bodyweight, in order to develop effective preventative and therapeutic strategies. These research efforts have identified gut hormones as key regulators of energy and glucose homeostasis and have implicated them in the pathogenesis of obesity, the weight recidivism that frequently plagues dietary interventions and the marked changes in eating behaviour, weight reduction and metabolic benefits that accompany bariatric surgery. Consequently, therapeutic strategies aimed at modulating gut hormone levels or targeting their receptors are now being using to treat people with obesity and obesity-associated diseases, such as type 2 diabetes, and represent the most promising therapeutic avenue to combat the obesity epidemic.
Introduction
Obesity, defined by a body mass index (BMI) of ≥30kg/m 2 , is a chronic progressive condition that results from excessive adipose tissue accumulation. Obesity-linked diseases, such as type 2 diabetes (T2DM), cardiovascular disease, musculoskeletal disorders, certain cancers and liver disease, impact upon health and reduce life expectancy [1] [2] [3] . Conversely, reductions in BMI improve both associated co-morbidity and increase life expectancy. It is estimated that by 2025, the global obesity prevalence will reach 18% in men and 21% in women [2] . Treatments for obesity to date have been limited and unsuccessful in addressing the challenge of the global obesity epidemic.
The key for developing new, effective, treatments for obesity lies in furthering our understanding of the mechanisms regulating bodyweight. The procurement of adequate nutrition is essential for survival and throughout the majority of human evolution food has been scarce, thus it is hardly surprising that multiple systems have evolved to ensure that eating is a priority. Energy homeostasis is controlled by neuronal circuits within the brain, which integrate peripheral signals of energy availability, originating from the gastrointestinal (GI) tract, adipose tissue, muscles, bones, higher cognitive centres and external environmental food cues [4] . Studies employing mouse transgenics, human genetics and human functional brain imaging have provided key insights into the neural pathways underpinning bodyweight regulation. The hypothalamus is recognised as a key region integrating peripheral signals to drive either orexigenic or anorexigenic responses, in a mutually exclusive manner [5] . The melanocortin-4 receptor (MC4R) has been identified as playing a key role in energy homeostasis; see Figure 1 for a more detailed overview [6] . The French philosopher Voltaire stated that "Nothing would be more tiresome than eating and drinking if God had not made them a pleasure as well as a necessity" and it is now clear that in addition to signals of net energy requirements and availability, the drive to eat is also strongly influenced by brain reward systems and these in turn are influenced by signals from the GI tract. Hedonic food cues, which are ever present in our obesogenic environment, drive the desire to eat and even in the absence of an energy requirement, can result in excess energy consumption, weight gain and ultimately obesity [5] . Thus, effective weight management strategies need to target both the homeostatic and hedonic regulation of eating and gut hormones have emerged as prime candidates. Here we review our current understanding of the role of gut hormones in the development and management of obesity.
The role of gut hormones in energy homeostasis, the pathogenesis and treatment of obesity

Gut hormones: role in energy homeostasis
The GI tract is the body's first point of contact with ingested nutrients and is metabolically highly active. Enteroendocrine cells (EECs) are distributed across the entire length of the GI tract. Following a meal, EECs sense nutrients and release a panoply of gut hormones, which act as autocrine, paracrine, and endocrine regulators of energy and glucose homeostasis [7] . For instance, peptide YY 36 (PYY), glucagon-like peptide 1 (GLP-1) and oxyntomodulin (OXM) are released from L-cells; they signal nutrient availability to the brain and have appetite-suppressing effects [7] . GLP-1 also has a profound incretin effect, enhancing glucose-dependent insulin release and inhibiting glucagon secretion [8] .
In the absence of nutrient intake, ghrelin, an orexigenic hormone, is secreted by P/D1 cells located primarily in the gastric fundus, leading to increased appetite and energy intake [9] . Circulating ghrelin levels peak prior to nutrient ingestion and decrease rapidly post-meal. Administration of ghrelin to humans promotes a feeling of hunger and stimulates energy intake [10] . The adipokine leptin acts as a signal of long term energy availability and promotes satiety, by modulating orexigenic neurons in the arcuate nucleus of the hypothalamus in an opposing manner to ghrelin [11] . Interestingly, MC4Rs
have been localised on P/D1 and L-cells and are thought to regulate ghrelin, GLP-1 and PYY secretion, adding an additional layer of complexity [12] . Table 1 summarises the main known gut hormones, their sites and mechanisms of action.
Importantly, gut hormones act synergistically; GLP-1 and PYY in combination, for instance, have a more potent effect on reducing energy intake, compared to either of the two hormones alone [13, 14] .
OXM, GIP and cholecystokinin (CCK) act synergistically with GLP-1 to enhance its effects [14] [15] [16] [17] .
Furthermore, gut hormones additionally influence energy homeostasis through interactions with the microbiome and bile acids; GLP-1, PYY and leptin act upon vagal signals; and OXM and amylin increase energy expenditure, though the mechanisms underlying these effects remain incompletely understood [18] [19] [20] [21] .
Gut hormones: influence on hedonic pathways
Hedonic factors are able to generate powerful physiological responses and override homeostatic signals of energy availability, leading to excess energy intake and weight gain. Brain functional imaging studies in humans have shown that gut hormones such as ghrelin, GLP-1 and PYY, modulate neural activity in brain reward regions altering the reward value of food [22] [23] [24] . Eating behavior is also strongly influenced by food cues, memory and social factors [5] . Exposure to food-related stimuli can stimulate changes in circulating gut hormone levels which in turn act upon brain reward pathways, either increasing in the case of ghrelin, or decreasing in the case of PYY, the reward value of food [25, 26] . Furthermore, the taste and smell of food, which are key contributors toward food choice, are also under the influence of gut hormone action. Gut hormones are present in saliva and their cognate receptors are present on taste buds and the olfactory bulb[27, 28]. The directionality of the relationship between weight gain and dysregulated gut hormone responses remains to be fully elucidated. However, a recent study in rats with diet-induced obesity, akin to a western diet, showed reduced circulating PYY and GLP-1 concentrations and a loss of circadian secretion profiles of PYY, GLP-1 and amylin [32] . In addition, sustained exposure to a high-fat diet in mice has been shown to lead to an increase in ghrelin-producing cells [33] . These findings suggest that high energy intake per se may chronically impair gut hormone responsiveness to ingested nutrients.
Gut hormones and the pathogenesis of obesity
Studies investigating the role of ghrelin in obesity, have shown blunted post-meal ghrelin suppression, loss of pre-meal peaks, along with reduced diurnal variability; these changes are thought to contribute to the lack of a regular meals and the frequent snacking behaviour often observed in individuals with obesity [9, 34] . In addition, the population and responsivity of intestinal EECs is reduced in people with obesity. A study using biopsied tissue from individuals with obesity also suggests that deregulation of intestinal cell differentiation underlies blunted gut hormone secretion [35] .
A recent report of a patient with leptin deficiency, highlights key interactions between gut hormones.
Leptin supplementation resulted in significant rises in meal-stimulated insulin and GLP-1, as well as PYY levels [36] . In the same study, ghrelin levels were decreased, highlighting the regulatory effect of leptin on ghrelin secretion and the interplay between leptin, GLP-1 and PYY. Interestingly, while resistance to the effects of insulin and leptin are seen in obesity, sensitivity to the effects of PYY, GLP-1 and OXM during exogenous administration is preserved, suggesting these hormones and their receptor systems offer a viable therapeutic target for obesity [17, 30 ]. . It is likely that methodological differences underlie these discrepancies and additional studies are warranted.
Gut hormone response to an energy deficit diet
Gut hormones as mediators of the success of bariatric surgery
Bariatric surgery is currently the most effective treatment for people with severe obesity leading to It is now established that lifestyle-induced weight loss and bariatric surgery differentially impact upon circulating gut hormone levels. Multiple studies have shown that bariatric surgery engenders elevations in nutrient-stimulated levels of several anorectic hormones including PYY and GLP-1 and a reduction in ghrelin levels is seen post-RYGB, with more marked reductions post-SG [51, 52] . These changes are present immediately post-surgery and sustained in the longer term [53, 54] . Table 2 summarises gut hormone changes following RYGB and SG and contrasts these with the changes following diet-induced weight loss. Furthermore, cross-sectional studies undertaken in patients with poor versus good weight loss post-surgery revealed that individuals with poor weight loss have increased appetite coupled with lower meal-stimulated GLP-1 and PYY and higher ghrelin levels, compared to those with good weight loss [55] . These studies provide observational evidence for a role of gut hormones in mediating the appetite-reducing effects of bariatric surgery [56] . This hypothesis is further supported by the finding that administration of the somatostatin analogue, octreotide, following bariatric surgery promotes appetite and weight gain [57] . More recently, blockade of GLP-1 and PYY in patients post-RYGB have been shown to lead to a 20% increase in energy intake, further implicating a key role for GLP-1 and PYY in mediating the appetite reduction observed postsurgery [58] .
The mechanisms underlying the post-surgery changes in gut hormones remain incompletely understood, however, increased exposure of EECs to ingested nutrients is thought to play a key role [59] . There is also emerging evidence that following bariatric surgery the number of EEC changes.
A recent study reported a reduction in total number of EECs and EECs containing gut hormones in the stomach and duodenum of people with obesity compared to lean individuals [35] . Importantly, 3 months post-SG, there was an increase in EECs normalising numbers to those seen in lean subjects.
Furthermore, the expression levels of transcription factors required for differentiation of absorptive and secretory cell lineages were altered, suggesting that the reduction in L-cell gut hormone secretion seen in obesity may be secondary to deregulation in differentiation of intestinal epithelial cell lineages, which is restored post-SG. 
Harnessing the gut for the prevention and treatment of obesity and metabolic diseases
Conclusion
Obesity and its associated diseases represent a major threat to global health. Research efforts aimed at furthering our understanding of energy homeostasis have identified gut hormones as key regulators of bodyweight acting upon homeostatic and hedonic brain circuits to modify eating behaviour.
Changes in circulating gut hormones are implicated in contributing to the development of obesity, the failure of lifestyle intervention and in mediating the profound beneficial effects of bariatric surgery.
Consequently, major research efforts are focused on harnessing the body's gut hormone system to treat obesity and obesity-associated diseases. Single agent approaches are already licensed for the treatment of people with T2DM or obesity with more efficacious combination approaches in development. Decreases energy intake, delays gastric emptying, causes glucose-dependent insulin secretion Effect of obesity on endogenous OXM is largely unknown, however exogenous administration is associated with weight loss [18] Cholecystokinin (CCK) Enteroendocrine I-and Lcells, pancreas and certain enteric and central neurons, in response to nutrient intake in particular lipids and protein [68] CCK-1 receptors in periphery and CCK-2 receptors in the brain [70] Inhibit energy intake, via CCK1R on vagal afferents, inhibit gastric secretion, stimulate insulin secretion [70] Satiety effect of CCK attenuated in obesity and CCK response to oleic acid infusion is reduced in people with overweight or obesity compared to normal weight subjects [70, 71] Glucosedependent insulinotropic polypeptide (GIP) Enteroendocrine K-cells in response to dietary lipids [68] GIP receptor in pancreatic islet cells, hypothalamus, adipose tissue [72] Stimulates insulin secretion, anti-apoptotic function in pancreatic beta cells, reduces energy intake [72] Some studies suggest GIP hypersecretion in people with obesity [72] Neurotensin (NT) Enteroendocrine L-cells, CNS , released in response to nutrient intake, in particular fat [73] NT receptors: NTR1, NTR2, NTR3 widely distributed in the brain and periphery [73] Reduces GI motility and gastric secretion, stimulates pancreatic and biliary secretion, facilitates fat translocation, act as an incretin. [ conversion to uroguanylin. [74] Gastric leptin Gastric chief cells and gastric endocrine P cells in response to energy intake and peptide hormones suck as CCK and insulin [11] Leptin receptors located in vagal afferents [76] Regulates energy intake; effect is dependent on nutritional status. In the fasted state, it inhibits vagal afferents, facilitating increased energy intake. In the fed state, stimulates vagal afferents with satiety-inducing effect. [11] Suggestion of reduce responses to gastric distension following energy intake. [76] Amylin Pancreatic beta cells, cosecreted with insulin, in response to nutrient ingestion and incretin hormones [61] Amylin-specific receptors (composed of the calcitonin receptor partnered with individual receptor-modifying proteins) in nucleus accumbens, the dorsal raphe, and the hindbrain area postrema [19] Supresses postprandial glucagon secretion, inhibition of energy intake and slows gastric emptying [61] Elevated in people with obesity, which may lead to down-regulation of amylin receptors and lessen the impact of postprandial amylin secretion on satiety and gastric emptying [61] FGF19
Tables
Terminal Ileum following FXR signalling from activation by bile acids [77] FGF receptors 1, 2, 3 and 4, located in hepatocytes, cardiac and skeletal muscle, kidneys, blood vessels and the CNS [77] Regulates glucose and lipid metabolism, stimulates hepatic protein and glycogen synthesis, increases energy expenditure and reduces energy intake. [77] Decreased FGF19 levels reported in people with obesity and insulin-resistance compared to normal weight people [77] Bile acids Liver hepatocytes [78] Farnesoid X Receptor (FXR) in the distal ileum and G protein-coupled TGR5 receptor on surface of L-cells [78] Stimulates glycogen synthesis, increases glycolysis and decreases gluconeogenesis, increasing insulin sensitive and improve glucose tolerance [78] Conflicting results, some studies show that people with obesity have lower postprandial BA levels than normal weight people Orexigenic Ghrelin P/D1-type cells in the gastric antrum and fundus and duodenum [30] Growth hormone secretagogue receptor type 1a (GHSR1a), after acylation by ghrelin O-acyltransferase (GOAT) into acylghrelin, hypothalamus, vagus nerve [9] Increase appetite, promotes nutrient intake, increases gastric emptying, gastric acid production, decreases insulin secretion [9] .
Ghrelin secretion is dysregulated in people with obesity. Diet induced obesity causes resistance to the effects of ghrelin in hypothalamic appetite regulating neurones. Decrease in ghrelin following energy ingestion is blunted in individuals with obesity. However, weight loss is associated with increases in ghrelin levels.
[30] Phase 1 Reduced energy intake and weight reduction in obese mice This study investigating the effect of high-fat diet-induced obesity on the daily rhythm and meal-stimuated secretion of gut peptide plasma levels in rats, demonstrated that animals with obesity had altered daily rhythms and meal-induced gut peptide levels even when consuming the same amount of calories than lean rats. A case report of a patient with leptin deficiency, highlighting key interactions between gut hormones. Leptin supplementation resulted in significant rises in meal-stimulated insulin and GLP-1, as well as PYY levels and reduced ghrelin levels were decreased, highlighting the regulatory effect of leptin on ghrelin secretion and the interplay between leptin and GLP-1/PYY. A functional brain imaging study administering the somatostatin analogue octreotide to patients post-RYGB demonstrated that suppression of GLP-1, PYY and FGF19 associated with an increased reward response to food images, which also correlated with PYY level reduction. This finding suggests that the altered gut hormone secretion profiles post-RYGB are likely mediating the reduction in food-related reward seen post-RYGB.
Figure Legends
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